Trial Profile
A clinical trial of IVIEW-1201 to treat and prevent COVID-19 infections in the eye
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2020
At a glance
- Drugs Povidone iodine (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 07 Apr 2020 New trial record
- 05 Apr 2020 According to an iView Therapeutics media release, the company's IVIEW-1201, a PVP-I gel-forming ophthalmic drop used to treat Acute Adenovirus Conjunctivitis could potentially be used to treat and prevent COVID-19 infections in the eye. The company has been working closely with China's CDE since January 2020 to initiate clinical trials.
Most Recent Events
Trial Overview
Purpose
This study will evaluate IVIEW-1201, a PVP-I gel-forming ophthalmic drop to treat and prevent COVID-19 infections in the eye.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | prevention, treatment | - |
Subjects
- Subject Type patients
- Sex male & female
Trial Details
Organisations
- Affiliations iView Therapeutics
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase II
- Location China
- Focus Therapeutic Use
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| Povidone iodinePrimary Drug | Ophthalmic | Drops |
IVIEW-1201
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 07 Apr 2020 | New trial record | New trial record Updated 07 Apr 2020 |
| 05 Apr 2020 | Other trial event | According to an iView Therapeutics media release, the company's IVIEW-1201, a PVP-I gel-forming ophthalmic drop used to treat Acute Adenovirus Conjunctivitis could potentially be used to treat and prevent COVID-19 infections in the eye. The company has been working closely with China's CDE since January 2020 to initiate clinical trials. Updated 07 Apr 2020 |
References
-
iView Therapeutics. iVIEW is developing a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of COVID-19 infection to curb the COVID-19 spread. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG